Understand the source comparison
Adamax Enhanced BDNF Upregulation: Research Application Comparison
Primary Pathway TrkB receptor agonism + CREB-mediated transcription Melanocortin receptor modulation, indirect BDNF CNTF pathway activation, glial-mediated support PGC-1α upregulation, FNDC5/irisin secretion 6–12 hours (Adamax), 48–72 hours (exercise) Adamax p
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Pathway
- TrkB receptor agonism + CREB-mediated transcription
- Melanocortin receptor modulation, indirect BDNF
- CNTF pathway activation, glial-mediated support
- PGC-1α upregulation, FNDC5/irisin secretion
- 6–12 hours (Adamax), 48–72 hours (exercise)
- Adamax produces direct, localized hippocampal BDNF synthesis unavailable through systemic interventions
- BDNF Increase Magnitude
- 280% hippocampal mRNA, 340% TrkB phosphorylation
- 45–60% serum BDNF (peripheral measurement)
- 120% cortical BDNF (glial-derived, not neuronal)
- 32% serum BDNF, poorly correlated with CNS levels
- Measured at 8–12 hours post-dose
- Adamax achieves transcriptional upregulation at the synthesis site, not peripheral spillover
- Synaptic Plasticity Markers
- Increased dendritic spine density, LTP amplitude +65%
- Improved attention, no structural plasticity data
- Enhanced neurogenesis (DG region), limited cortical effect
- Variable LTP effects, inconsistent across studies
- LTP measurable 24–48 hours post-treatment
- Direct TrkB activation produces measurable structural changes; indirect methods show functional but not morphological effects
- Blood-Brain Barrier
- Crosses via LAT1 transporter (confirmed via radiolabeling)
- Limited CNS penetration, primarily peripheral effects
- Poor penetration unless administered intranasally
- N/A. Peripheral irisin crosses minimally
- Penetration confirmed within 90 minutes
- CNS-active peptides require verified BBB transport; peripheral BDNF measurements mislead efficacy assessment
- Research Application
- Cognitive decline models, synaptic injury, mood disorder pathways
- Attention and memory performance studies
- Neurogenesis and hippocampal volume research
- Baseline neuroplasticity in healthy populations
- Context-dependent
- Use Adamax for direct BDNF pathway investigation; use comparators for orthogonal mechanisms
- This table reflects findings from peer-reviewed studies published in Journal of Neuroscience, Molecular Psychiatry, and Neuropharmacology between 2021–2025. Adamax enhanced BDNF upregulation occupies a distinct mechanistic niche. It's not a substitute for exercise-induced neuroplasticity but a tool for investigating the transcriptional machinery that exercise indirectly modulates.